Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Much data support a role for central nervous system antigen-specific antibodies in the pathogenesis of multiple sclerosis (MS). The effects of inducing a decrease in (auto)antibody levels on MS or experimental autoimmune encephalomyelitis (EAE) through specific blockade of FcRn, however, remain unexplored. We recently developed engineered antibodies that lower endogenous IgG levels by competing for binding to FcRn. These Abdegs ("antibodies that enhance IgG degradation") can be used to directly assess the effect of decreased antibody levels in inflammatory diseases. In the current study, we show that Abdeg delivery ameliorates disease in an EAE model that is antibody dependent. Abdegs could therefore have promise as therapeutic agents for MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
Vaccaro, C., Zhou, J., Ober, R. J., & Ward, E. S. (2005) · Nature Biotechnology · doi:10.1038/nbt1143 · Cited by 407 · cited 3×
“4.(9) In the presence of these inhibitors, competing IgGs are driven into the degradative, lysosomal pathway within cells.”
BackgroundSelf-citationVisualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn
Ober, R. J., Martinez, C., Vaccaro, C., Zhou, J., & Ward, E. S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2021 · Cited by 314
Self-citationAnalyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery
Gan, Z., Ram, S., Vaccaro, C., Ober, R. J., & Ward, E. S. (2009) · Traffic · doi:10.1111/j.1600-0854.2009.00887.x · Cited by 76
Self-citation
Cited by
The Neonatal Fc Receptor (FcRn): A Misnomer?
Pyzik, M., Sand, K. M. K., Hubbard, J. J., Andersen, J. T., Sandlie, I., & Blumberg, R. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01540 · Cited by 429
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
Ulrichts, P., Guglietta, A., Dreier, T., van Bragt, T., Hanssens, V., Hofman, E., Vankerckhoven, B., Verheesen, P., Ongenae, N., Lykhopiy, V., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97911 · Cited by 427
“The therapeutic applicability of this concept was demonstrated in various murine models of IgG-mediated autoimmunity (16, 17).”
BackgroundSelf-citationPharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liu, L. (2018) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 390
The therapeutic age of the neonatal Fc receptor
Pyzik, M., Kozicky, L. K., Gandhi, A. K., & Blumberg, R. S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00821-1 · Cited by 288
Khare, P., Challa, D. K., Devanaboyina, S. C., Velmurugan, R., Hughes, S., Greenberg, B. M., Ober, R. J., & Ward, E. S. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.09.002 · Cited by 31
Self-citation
Metadata
- Authors
- Challa, D. K., Bussmeyer, U., Khan, T., Montoyo, H. P., Bansal, P., Ober, R. J., & Ward, E. S.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2013-09
- Volume
- 5
- Issue
- 5
- Pages
- 655-659
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2024627890
- Cited by
- 60
- References
- 4
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis. https://app.cochat.ai/papers/10.4161/mabs.25439
- The paper
- Challa, D. K., Bussmeyer, U., Khan, T., Montoyo, H. P., Bansal, P., Ober, R. J., & Ward, E. S. (2013). Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis. mAbs. https://doi.org/10.4161/mabs.25439
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.